Navigation Links
Building 'smart' cell-based therapies

A Northwestern University synthetic biology team has created a new technology for modifying human cells to create programmable therapeutics that could travel the body and selectively target cancer and other sites of disease.

Engineering cell-based, biological devices that monitor and modify human physiology is a promising frontier in clinical synthetic biology. However, no existing technology enabled bioengineers to build such devices that sense a patient's physiological state and respond in a customized fashion.

"The project addressed a key gap in the synthetic biology toolbox," says Joshua Leonard, assistant professor of chemical and biological engineering in Northwestern's McCormick School of Engineering and Applied Science. "There was no way to engineer cells in a manner that allowed them to sense key pieces of information about their environment, which could indicate whether the engineered cell is in healthy tissue or sitting next to a tumor."

Funded by the National Academies Keck Futures Initiative and the Defense Advanced Research Projects Agency, the research is available to read online in the journal ACS Synthetic Biology.

Leonard's team worked for nearly four years to close this gap. The end result is a protein biosensor that sits on the surface of a cell and can be programmed to sense specific external factors. For example, the engineered cell could detect big, soluble protein molecules that indicate that it's next to a tumor. When the biosensor detects such a factor, it sends a signal into the engineered cell's nucleus to activate a gene expression program, such as the production of tumor-killing proteins or chemicals. Since this toxic program would be activated only near tumor cells, such an approach could minimize side effects as well as improve therapeutic benefits.

Called a Modular Extracellular Sensor Architecture (MESA), the biosensor platform is completely self-contained so that several different biosensors can be present in a single cell without interfering with one another, allowing bioengineers to build increasingly sophisticated functional programs. The platform is also highly modular, enabling the biosensors to be customized to recognize factors of relevance to various patients' needs.

"By linking the output of these biosensors to genetic programs, one can build in a certain logical command, such as 'turn the output gene on when you sense this factor but not that factor,'" Leonard explains. "In that way, you could program a cell-based therapy to specify which cells it should kill."

Leonard says doctors could potentially collect immune cells from a patient's body, engineer the cells using MESA, and put them back into the patient. From there, the cells would do the work of detecting cancer or the disease they are designed to identify.

This is the first completely ground-up engineering of a receptor, and now that the core technology has been established, Leonard's team is moving forward to program cells to recognize specific tumor-associated factors. They are also looking toward applications beyond advanced cell-based therapies.

"This seems to be what always happens in synthetic biology," he says. "When you start building something, you first learn a lot about the system that you are trying to modify. In the end, you come up with not only useful applications but tools that facilitate basic science."


Contact: Megan Fellman
Northwestern University

Related medicine news :

1. Body Building, Diet Supplements Linked to Liver Damage: Study
2. Germ Culprits in Moldy, Water-Damaged Buildings Identified
3. Building a better Rift Valley fever vaccine
4. Heuer M.D. Research Announces CardiaShred™ - First Medical Doctor Formulated, Heart Healthy Weight Loss, Energy and Lean Muscle Building Supplement
5. Kessler Foundation presents Brain Injury: From Research to Rebuilding Lives on Sept. 27-28
6. Rebuilding a whole heart for children born with only half of 1
7. UC research explores relationship-building program for male same-sex couples
8. Dental Marketing has been Featured in The LA Daily News for their Specialized Practice Building Solutions in the Dental Industry
9. Steering stem cells to become 2 different building blocks for new blood vessels
10. Rebuilding blood vessels through gene therapy
11. Visual Impact Muscle Building: Review Examining Rusty Moore's Training Program Released By
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three ... learned from three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... DataTrade Solutions Inc., a Healthcare IT consulting, development and support company. The purchase ... technical experience available within DataTrade to extend the services currently provided by Healthjump. ...
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... ), a leading provider of enterprise Time and Attendance/Workforce Management cloud-based ... in the Microsoft Partner Program with competencies in the Application Development, demonstrating ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... 2016. In 2016, expected coding changes are likely to include new codes for ... It’s not easy to understand the effects of code changes in musculoskeletal, radiology ...
(Date:11/29/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... Women's Excellence is once again accredited by the American Institute ... peer review process that allows practices to demonstrate that they meet or ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
(Date:11/30/2015)... BOSTON , November 30, 2015 ... new medicines directed at up to 10 G protein-coupled ... PFE ) to research and develop potential new ... (GPCR) targets across multiple therapeutic areas. --> ... and development company and wholly-owned subsidiary of Sosei Group ...
(Date:11/30/2015)... , November 30, 2015 ... or the "Company") announced today that it was informed by ... and Drug Safety (MFDS) has approved its Exablate Neuro ... --> --> Insightec,s Exablate ... treatment alternative that combines two technologies: Focused Ultrasound, which ...
Breaking Medicine Technology: